Credit Suisse Maintains Outperform on Boston Beer Co, Lowers Price Target to $400
Credit Suisse analyst Kaumil Gajrawala maintains Boston Beer Co (NYSE:SAM) with a Outperform and lowers the price target from $620 to $400.
Piper Sandler Maintains Overweight on NVIDIA, Lowers Price Target to $235
Piper Sandler analyst Harsh Kumar maintains NVIDIA (NASDAQ:NVDA) with a Overweight and lowers the price target from $250 to $235.
Credit Suisse Upgrades Taylor Morrison Home to Outperform, Announces $33 Price Target
Credit Suisse analyst Daniel Oppenheim upgrades Taylor Morrison Home (NYSE:TMHC) from Neutral to Outperform and announces $33 price target.
Barclays Upgrades Element Solutions to Overweight, Lowers Price Target to $22
Barclays analyst Michael Leithead upgrades Element Solutions (NYSE:ESI) from Equal-Weight to Overweight and lowers the price target from $24 to $22.
Morgan Stanley Downgrades New Relic to Equal-Weight, Announces $64 Price Target
Morgan Stanley analyst Sanjit Singh downgrades New Relic (NYSE:NEWR) from Overweight to Equal-Weight and announces $64 price target.
B of A Securities Upgrades Flowserve to Neutral
B of A Securities analyst Andrew Obin upgrades Flowserve (NYSE:FLS) from Underperform to Neutral.
Wolfe Research Downgrades Moelis & Co to Underperform, Announces $42 Price Target
Wolfe Research analyst Steven Chubak downgrades Moelis & Co (NYSE:MC) from Peer Perform to Underperform and announces $42 price target.
BMO Capital Downgrades Kura Sushi USA to Market Perform, Announces $80 Price Target
BMO Capital analyst Andrew Strelzik downgrades Kura Sushi USA (NASDAQ:KRUS) from Outperform to Market Perform and announces $80 price target.
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Lowers Price Target to $54
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $60 to $54.
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Lowers Price Target to $2.5
HC Wainwright & Co. analyst Yi Chen maintains Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and lowers the price target from $3 to $2.5.